Ursodeoxycholic acid accelerates bile acid enterohepatic circulation.
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
16
11
2018
revised:
14
04
2019
accepted:
20
04
2019
pubmed:
12
5
2019
medline:
9
9
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
Ursodeoxycholic acid (UDCA) is the first-line treatment for primary biliary cholangitis, but its effects on the enterohepatic circulation of bile acid (BA) have been under-investigated. Therefore, we studied the influence of UDCA on BA enterohepatic circulation in vivo and the mechanisms by which UDCA affects the BA kinetics. Mice were treated with UDCA and other BAs to observe changes in BA pool and BA transporters involved in enterohepatic circulation. Isotope dilution techniques and biochemical analyses were applied to study BA kinetics after oral administration of UDCA, and the mechanism involved. Oral administration of UDCA in mice reduced the overall BA pool and produced a unique BA profile with high-abundance conjugated UDCA species, including tauroursodeoxycholic acid (TUDCA) and GUDCA. We found increased expression of several main BA transporters in the ileum and liver. BA kinetic experiment showed that feeding UDCA shortened cycling time of BA and accelerated BA enterohepatic circulation. Additionally, we found evidence that the effect of UDCA administration on accelerating BA enterohepatic circulation was due to the inhibition of farnesoid X receptor (FXR) signalling in the ileum and FGF15/19 in the liver. Oral administration of UDCA produced a unique BA profile with high-abundance TUDCA and GUDCA and significantly accelerated BA enterohepatic circulation through the inhibition of intestinal FXR signalling and reduced level of FGF15/19, which in turn, induced the expression of BA transporters in the liver. These findings highlight a critical role for UDCA in maintaining the homeostasis of BA enterohepatic circulation in vivo.
Sections du résumé
BACKGROUND AND PURPOSE
Ursodeoxycholic acid (UDCA) is the first-line treatment for primary biliary cholangitis, but its effects on the enterohepatic circulation of bile acid (BA) have been under-investigated. Therefore, we studied the influence of UDCA on BA enterohepatic circulation in vivo and the mechanisms by which UDCA affects the BA kinetics.
EXPERIMENTAL APPROACH
Mice were treated with UDCA and other BAs to observe changes in BA pool and BA transporters involved in enterohepatic circulation. Isotope dilution techniques and biochemical analyses were applied to study BA kinetics after oral administration of UDCA, and the mechanism involved.
KEY RESULTS
Oral administration of UDCA in mice reduced the overall BA pool and produced a unique BA profile with high-abundance conjugated UDCA species, including tauroursodeoxycholic acid (TUDCA) and GUDCA. We found increased expression of several main BA transporters in the ileum and liver. BA kinetic experiment showed that feeding UDCA shortened cycling time of BA and accelerated BA enterohepatic circulation. Additionally, we found evidence that the effect of UDCA administration on accelerating BA enterohepatic circulation was due to the inhibition of farnesoid X receptor (FXR) signalling in the ileum and FGF15/19 in the liver.
CONCLUSION AND IMPLICATIONS
Oral administration of UDCA produced a unique BA profile with high-abundance TUDCA and GUDCA and significantly accelerated BA enterohepatic circulation through the inhibition of intestinal FXR signalling and reduced level of FGF15/19, which in turn, induced the expression of BA transporters in the liver. These findings highlight a critical role for UDCA in maintaining the homeostasis of BA enterohepatic circulation in vivo.
Identifiants
pubmed: 31077342
doi: 10.1111/bph.14705
pmc: PMC6637225
doi:
Substances chimiques
Carrier Proteins
0
Membrane Glycoproteins
0
Receptors, Cytoplasmic and Nuclear
0
bile acid binding proteins
0
Fibroblast Growth Factors
62031-54-3
Ursodeoxycholic Acid
724L30Y2QR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2848-2863Subventions
Organisme : NIMHD NIH HHS
ID : U54 MD007584
Pays : United States
Informations de copyright
© 2019 The British Pharmacological Society.
Références
Br J Pharmacol. 2015 Jul;172(14):3461-71
pubmed: 26114403
Cancer Res. 2017 Jun 15;77(12):3352-3363
pubmed: 28416481
Mol Aspects Med. 2017 Aug;56:34-44
pubmed: 28442273
Nat Commun. 2015 Dec 15;6:10166
pubmed: 26670557
Int J Cancer. 2012 Jun 15;130(12):2771-82
pubmed: 21805474
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
Gastroenterology. 2005 Aug;129(2):476-85
pubmed: 16083704
J Lipid Res. 2009 Dec;50(12):2340-57
pubmed: 19498215
Clin Sci (Lond). 2011 Dec;121(12):523-44
pubmed: 21854363
Br J Pharmacol. 2017 Dec;174 Suppl 1:S208-S224
pubmed: 29055032
Toxicol Appl Pharmacol. 2015 Feb 15;283(1):57-64
pubmed: 25582706
Compr Physiol. 2013 Jul;3(3):1191-212
pubmed: 23897684
Pharm Res. 2007 Oct;24(10):1803-23
pubmed: 17404808
J Proteome Res. 2016 Apr 1;15(4):1126-34
pubmed: 25964117
J Hepatol. 2011 May;54(5):1011-9
pubmed: 21145828
Cell Metab. 2009 Jan 7;9(1):35-51
pubmed: 19117545
Science. 1999 May 21;284(5418):1362-5
pubmed: 10334992
FASEB J. 2013 Sep;27(9):3583-93
pubmed: 23709616
Clin Chim Acta. 1988 Jul 15;175(2):143-55
pubmed: 3044647
J Hepatol. 2015 Jun;62(6):1398-404
pubmed: 25617503
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Nat Med. 2018 Dec;24(12):1919-1929
pubmed: 30397356
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
J Lipid Res. 2001 Nov;42(11):1923-9
pubmed: 11714862
Clin Liver Dis. 2004 Feb;8(1):67-81, vi
pubmed: 15062194
Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1;312(6):G550-G558
pubmed: 28360029
Cell Metab. 2005 Oct;2(4):217-25
pubmed: 16213224
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359
pubmed: 29055034
Hepatology. 1996 Jun;23(6):1464-7
pubmed: 8675165
Br J Pharmacol. 2019 Aug;176(16):2848-2863
pubmed: 31077342
Gut. 2011 Mar;60(3):387-96
pubmed: 21115542
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
J Biol Chem. 2003 Oct 24;278(43):41930-7
pubmed: 12917447
Nat Rev Drug Discov. 2008 Aug;7(8):678-93
pubmed: 18670431
Am J Kidney Dis. 2018 Jan;71(1):27-34
pubmed: 28801122
J Biol Chem. 2005 Feb 25;280(8):6960-8
pubmed: 15563450
J Hepatol. 2013 Jan;58(1):155-68
pubmed: 22885388
Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G193-204
pubmed: 26608189
Pflugers Arch. 2004 Feb;447(5):566-70
pubmed: 12851823
J Hepatol. 2004 Mar;40(3):539-51
pubmed: 15123373
Autoimmun Rev. 2017 Sep;16(9):885-896
pubmed: 28698093
Science. 1999 May 21;284(5418):1365-8
pubmed: 10334993
Toxicol Sci. 2014 Oct;141(2):538-46
pubmed: 25055961
Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43
pubmed: 17162245
J Lipid Res. 1984 Dec 1;25(12):1313-9
pubmed: 6530587
Nat Med. 2006 Nov;12(11):1253-5
pubmed: 17072310
Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G60-6
pubmed: 15591588
Physiol Rev. 2003 Apr;83(2):633-71
pubmed: 12663868
Hepatology. 2004 Jul;40(1):149-56
pubmed: 15239098
Hepatology. 2010 Aug;52(2):472-9
pubmed: 20683947
Hepatology. 2004 Mar;39(3):770-8
pubmed: 14999696
Br J Pharmacol. 2017 Dec;174 Suppl 1:S360-S446
pubmed: 29055035
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
Hepatology. 2017 Nov;66(5):1631-1643
pubmed: 28498614